2025-07-15 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data.

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and provides a wide range of healthcare solutions.

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **MRK Cumulative Return:** 33.05%
*   **VOO Cumulative Return:** 95.85%
*   **Relative Divergence:**
    *   **Current:** -95.4
    *   **Min:** -99.5
    *   **Max:** 23.1
    *   **Relative Deviation:** 3.3

**Analysis:**

MRK has significantly underperformed the S&P 500 (VOO) over the analyzed period. The cumulative return of MRK is substantially lower than that of VOO. The relative divergence of -95.4 indicates that MRK's performance is currently near the lower end of its historical range compared to VOO. Relative Deviation of 3.3 means MRK's relative performance (compared to VOO) is near the bottom of its historical range.

**Alpha/Beta Analysis Table:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap (B) |
|------------|---------|--------|---------|-------|---------|
| 2015-2017  | 5.0%    | 58.2%  | -24.0%  | -0.0  | 134.8   |
| 2016-2018  | 43.0%   | 66.4%  | 25.0%   | -0.1  | 183.1   |
| 2017-2019  | 40.0%   | 66.4%  | 11.0%   | 0.3   | 217.9   |
| 2018-2020  | 20.0%   | 66.4%  | 0.0%    | 0.3   | 196.0   |
| 2019-2021  | -1.0%   | 65.6%  | -50.0%  | 0.3   | 192.4   |
| 2020-2022  | 13.0%   | 69.5%  | 11.0%   | 0.3   | 278.6   |
| 2021-2023  | 31.0%   | 69.5%  | 13.0%   | 0.3   | 273.8   |
| 2022-2024  | -7.0%   | 69.5%  | -33.0%  | 0.2   | 249.8   |
| 2023-2025  | -52.0%  | 61.4%  | -99.0%  | 0.5   | 210.1   |

**Analysis of Alpha/Beta Table:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows variable performance across different periods, with significant declines in recent years (2023-2025).
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant volatility and risk.
*   **Alpha:** The Alpha values are mostly negative, especially in recent periods (2023-2025: -99.0%), meaning MRK has underperformed its benchmark on a risk-adjusted basis.
*   **Beta:** The Beta values are generally low (around 0.2-0.3), suggesting that MRK is less sensitive to market movements compared to the S&P 500.
*   **Cap (B):** The market capitalization shows fluctuations, reflecting changing investor sentiment and market conditions.

### 2. Recent Stock Price Movements

**Key Numbers:**

*   **Current Price:** $83.67
*   **Previous Close:** $83.36
*   **Change:** 0.37
*   **5-Day Moving Average:** 83.72
*   **20-Day Moving Average:** 81.0585
*   **60-Day Moving Average:** 79.5832

**Analysis:**

The stock price shows a slight increase from the previous close. The current price is slightly below the 5-day moving average but above both the 20-day and 60-day moving averages, indicating a short-term upward trend.

### 3. Market Risk Indicator and Related Metrics

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.3372 (Low Risk)
*   **RSI:** 65.88
*   **PPO:** 0.4235
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **20-Day Relative Divergence Change:** 0.2 (+)
*   **Expected Return (%):** -315.5%

**Analysis:**

*   **MRI:** The MRI of 0.3372 suggests a low-risk environment for the stock.
*   **RSI:** The RSI of 65.88 is approaching overbought territory (typically above 70), indicating the stock may be due for a pullback.
*   **PPO:** The PPO of 0.4235 indicates that the short-term moving average is slightly above the long-term moving average, confirming the short-term upward trend.
*   **Hybrid Signal:** The Hybrid Signal recommends buying 80% of available cash with caution, given the low MRI.
*   **20-Day Relative Divergence Change:** The positive change of 0.2 in relative divergence suggests a short-term upward trend.
*   **Expected Return:** The highly negative expected return (-315.5%) suggests that long-term returns are projected to be significantly lower than the S&P 500.

The price change of 0.37 from the previous close is not significant enough to warrant a mention of "급반등" or "급하락."

### 4. Recent News & Significant Events

*   **July 12, 2025:** Major business developments, regulatory changes, or market events.
*   **July 15, 2025:** Analysts discussing performance and outlook in context of industry trends and global economic factors.
*   **July 11, 2025:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **July 14, 2025:** Market experts highlighting risks and opportunities, advising investors to monitor news and announcements.

**Analysis:**

Recent news suggests the stock is experiencing volatility and is subject to ongoing analysis and market events. Investors should monitor news and company announcements closely.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-05-02 | 2.01 | 15.53 B$    |
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2024-08-05 | 2.15 | 16.11 B$    |
| 2024-05-03 | 1.88 | 15.78 B$    |
| 2025-05-02 | 1.88 | 15.78 B$    |

**Analysis:**

The earnings data reveals fluctuations in both EPS (Earnings Per Share) and revenue. There is a notable decrease in EPS from August 2024 (2.15) to November 2024 (1.25), followed by an increase in May 2025 (2.01), then a reduction on 2025-05-02. Revenue has also fluctuated, indicating some volatility in the company's financial performance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-03-31 | $48.34B   | 10.51%    |
| 2024-12-31 | $46.31B   | 8.08%     |
| 2024-09-30 | $44.50B   | 7.09%     |
| 2024-06-30 | $43.58B   | 12.52%    |
| 2024-03-31 | $40.36B   | 11.80%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue is relatively stable across the quarters, with a slight peak in Q3 2024. The profit margins are consistently high, around 75-78%, indicating strong profitability.
*   **Capital and Profitability:** Equity has been increasing over the quarters, indicating growth in the company's net assets. ROE (Return on Equity) fluctuates, with a high in Q2 2024 and a low in Q3 2024, reflecting changes in the company's ability to generate profits from shareholders' investments.

### 7. Overall Analysis and Summary

**Summary:**

*   **Underperformance vs. S&P 500:** MRK has significantly underperformed the S&P 500, with a very low relative divergence.
*   **Financial Health:** High profit margins and increasing equity indicate strong financial health, but ROE fluctuations and volatile earnings data suggest potential operational inefficiencies.
*   **Risk & Volatility:** High MDD and recent news of stock volatility suggest caution is warranted.
*   **Recent News:** Recent news highlights significant developments and volatility, indicating that investors should closely monitor the stock.
*   **Technical Indicators:** The RSI is approaching overbought conditions, while the PPO confirms a short-term upward trend.
*   **Market Risk:** The MRI suggests a low-risk environment for the stock.
*   **Recommendation:** Given the recent underperformance, volatility, and projected long-term returns being significantly lower than the S&P 500, cautious investing or reevaluation of the investment thesis is recommended.

**In Conclusion:**

While Merck & Co Inc (MRK) exhibits financial stability and strong profit margins, its underperformance relative to the S&P 500 and the negative projected long-term return warrant caution. Investors should closely monitor the stock and consider its risk profile before making investment decisions.
